One CAR T-Cell Therapy for Multiple Myeloma Tops Another in Propensity Matched Study

(MedPage Today) -- SAN DIEGO -- In a propensity-matched comparison of two CAR T-cell therapies, ciltacabtagene autoleucel (cilta-cel, Carvykti) demonstrated better efficacy than idecabtagene vicleucel (ide-cel, Abecma) for relapsed/refractory...